10-K: Sight Sciences 2025 Annual Report: Glaucoma Flat, Dry Eye Down Amid Restructuring

Sight Sciences reports a net loss of $38.4 million for 2025, with flat Interventional Glaucoma revenue and a significant decline in Interventional Dry Eye sales, alongside a 20% workforce reduction.

Summary

• Net loss for 2025 was $38.4 million, an improvement from $51.5 million in 2024.
• Total revenue decreased by 3.1% to $77.4 million in 2025 from $79.9 million in 2024.
• Interventional Glaucoma revenue was $75.7 million in 2025, a slight decrease of 0.2% from $75.9 million in 2024, primarily due to reimbursement coverage changes and increased competition.
• Interventional Dry Eye revenue was $1.6 million in 2025, a significant decrease of 58.7% from $4.0 million in 2024, attributed to a strategic shift focusing on reimbursed market access.
• Overall gross margin improved to 86.2% in 2025 from 85.5% in 2024.
• Research and Development (R&D) expenses decreased by 18.8% to $14.6 million in 2025, partly due to a $2.7 million reduction in personnel costs from an August 2025 reduction in force.
• Selling, General and Administrative (SG&A) expenses decreased by 11.6% to $89.2 million in 2025, driven by a $5.4 million decrease in legal expenses and a $4.7 million decrease in personnel costs from the August 2025 reduction in force.
• The company implemented a targeted restructuring plan in Q3 2025, reducing its global workforce by approximately 20% and cutting operating expenses.
• Cash and cash equivalents were $92.0 million as of December 31, 2025, down from $120.4 million in 2024.
• Accumulated deficit reached $384.7 million as of December 31, 2025.
• A $34 million jury verdict was awarded in the company's favor in April 2024 in patent litigation against Alcon, but the outcome is subject to post-trial motions, potential appeal, and ongoing ex parte reexaminations by the USPTO.
• Two Medicare Administrative Contractors (MACs), Novitas and FCSO, established jurisdiction-wide pricing for CPT code 0563T (TearCare) retroactive to January 1, 2025, leading to improved Q4 2025 sales performance for Interventional Dry Eye.
• The interest-only period for the Hercules Loan Agreement was extended to February 1, 2027, and the available undrawn tranche increased from $15.0 million to $25.0 million, subject to approval.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a challenging period for Sight Sciences, marked by declining revenue in both segments, significant cash burn from operations, and ongoing legal and reimbursement hurdles. While cost-cutting and some positive clinical data are noted, the overall financial performance and market headwinds suggest a cautious outlook.

Positives

• Net loss decreased from $51.5 million in 2024 to $38.4 million in 2025, representing a 25.4% improvement.
• Overall gross margin improved to 86.2% in 2025 from 85.5% in 2024.
• Interventional Dry Eye gross margin significantly increased to 59.3% in 2025 from 46.2% in 2024, driven by increased average selling prices.
• Research and Development (R&D) expenses decreased by 18.8% ($3.4 million) and Selling, General and Administrative (SG&A) expenses decreased by 11.6% ($11.7 million) due to cost-cutting measures and a workforce reduction.
• A positive jury trial verdict of $34 million (comprising $5.5 million lost profits and $28.5 million royalty damages) was awarded in patent litigation against Alcon in April 2024.
• Two MACs (Novitas and FCSO) established jurisdiction-wide pricing for TearCare (CPT code 0563T) retroactive to January 1, 2025, leading to improved Q4 2025 sales performance for Interventional Dry Eye.
• Published clinical data (SAHARA Phase 3 in August 2025) demonstrated durability of TearCare treatment effect over 24 months, with 66% of participants requiring no additional treatment after initial therapy and a Month 5 retreatment.
• A Budget Impact Analysis (BIA) published in December 2024 estimated annual savings of $36.87 per member per year for a hypothetical health plan with 20% TearCare market share.
• A Cost Utility Analysis (CUA) published in July 2025 showed TearCare resulted in lower per-patient annual costs ($4,916) and higher quality-adjusted life years (0.76) compared to cyclosporine 0.05% ($5,819 and 0.74 QALYs).
• The OMNI Surgical System family of products received EU MDR approval on December 5, 2023.
• The company received UKCA certification for the OMNI family of products on March 1, 2024.
• The interest-only period for the Hercules Loan Agreement was extended to February 1, 2027, providing additional financial flexibility.
• The available undrawn tranche under the Hercules Loan Agreement increased from $15.0 million to $25.0 million, subject to approval.

Negatives

• Total revenue decreased by 3.1% year-over-year to $77.4 million in 2025.
• Interventional Glaucoma revenue was nearly flat, decreasing by 0.2% in 2025, impacted by adverse reimbursement changes and increased competition.
• Interventional Dry Eye revenue saw a substantial 58.7% decrease to $1.6 million in 2025, reflecting a strategic shift that initially reduced demand.
• The Final LCDs (effective November 2024) adopted a non-coverage policy for multiple MIGS procedures performed simultaneously with aqueous shunt/stent procedures, reducing overall MIGS claims volumes.
• The Medicare Physician Fee Schedule amount for CPT code 66174 (canaloplasty) has been reduced multiple times, from approximately $950 in 2021 to $545 in 2026, making it less attractive to ECPs.
• Limited reimbursement coverage for TearCare exists outside of Novitas and FCSO jurisdictions, with patients typically paying out-of-pocket.
• The company experienced recent declines in the number of surgeons being trained on OMNI.
• Ongoing significant losses, with an accumulated deficit of $384.7 million as of December 31, 2025.
• Cash and cash equivalents decreased from $120.4 million in 2024 to $92.0 million in 2025.
• Investment income decreased by 32.9% due to lower investment balances and lower yields.
• Interest expense increased by 10.3% due to a higher outstanding principal balance under the Hercules Loan Agreement.
• A substantial majority of products are expected to be manufactured in China through 2026, subjecting the company to U.S. tariffs on Chinese imports, which negatively impacts gross margins.
• Ongoing patent reexamination proceedings by Alcon challenge the validity of the patents for which the company received a $34 million jury verdict, potentially impacting the award.
• Trademark litigation in the UK and EU regarding the OMNI trademark could lead to abandonment of the mark in those markets if unsuccessful.
• A workforce reduction of approximately 20% of the global workforce was implemented in Q3 2025.

Risks

• The company is an early-stage company with a history of significant losses and expects to incur losses in the future, making it difficult to achieve or sustain profitability.
• High dependence on revenue from OMNI and TearCare sales, with inability to successfully execute growth strategy negatively affecting financial results.
• Inability to secure or maintain adequate levels of third-party coverage and reimbursement for procedures using Interventional Glaucoma or Interventional Dry Eye products, or rescission/modification of coverage.
• The market for products is highly competitive and could grow increasingly competitive, with competitors potentially having greater resources, longer operating histories, or more established products.
• Adoption of products depends on appropriate physician training, practice, and patient selection, with risks of off-label use or inadequate training leading to negative outcomes.
• Development of products for expanded indications depends on positive clinical data, and regulatory authorities may require more long-term data, delaying or preventing clearances.
• Reliance on third parties for manufacturing and supply, with many single-source providers and substantial production in China, exposing the company to supply chain disruptions, tariffs, and geopolitical tensions.
• Uncertainty in current global economic and political conditions could adversely affect product demand and costs, leading to results differing from expectations.
• Risk of providing inadequate training, failing to maintain effective sales and marketing capabilities, or failing to develop broad brand awareness cost-effectively.
• Limited experience in training ECPs on, and marketing and selling, TearCare products, which could adversely affect customer perceptions and adoption.
• Products are designed for a limited number of procedures, and the total addressable market may be smaller than estimated.
• Inability to accurately forecast customer demand for products and manage inventory could materially harm results of operations.
• Long-term growth depends on capturing market share, enhancing products, maintaining appropriate reimbursement, expanding indications, and developing additional products in a timely manner.
• Security breaches, loss of data, and other disruptions could compromise sensitive information or prevent access to critical information, exposing the company to liability.
• International operations expose the company to market, legal, regulatory, political, operational, financial, and economic risks.
• Success depends on the ability to obtain, maintain, and protect intellectual property rights, with risks of costly and time-consuming litigation or administrative proceedings.
• Products, business practices, and operations are subject to extensive government regulation and oversight in the United States and elsewhere, with risks of non-compliance.
• Failure to receive, or delays in receiving, necessary clearances, certifications, or approvals for future products or modifications to current products.
• The price of common stock may fluctuate substantially or decline regardless of operating performance, leading to potential investment loss.
• Failure to maintain effective internal control over financial reporting and effective disclosure controls and procedures could adversely affect investor confidence.
• Provisions in corporate charter documents and Delaware law could make an acquisition of the company more difficult and prevent attempts by stockholders to replace management.
• Need for additional funding to finance planned operations, with risks of not being able to raise capital on acceptable terms, if at all.
• Risk of potential warranty claims on products.
• Collaborations, in-licensing arrangements, joint ventures, strategic alliances, or partnerships with third parties may not result in commercially viable products or significant revenue.
• Dependence on senior management team, and the loss of key employees or inability to attract and retain highly skilled employees.
• The use, misuse, or off-label use of products may result in injuries that lead to product liability suits.
• Significant amount of debt may affect the ability to operate the business and secure additional financing in the future.
• Failure to manage acquisitions or investments, or to integrate them with the existing business, could have a material adverse effect.
• Adverse effects from violations of the FCPA and similar worldwide anti-bribery laws, anti-boycott, anti-money laundering laws, and export regulations.
• Epidemic diseases, or the perception of their effects, may have an adverse effect on business, financial condition, results of operations, and cash flows.
• Ability to use net operating loss carryforwards and certain other tax attributes may be limited.
• Uncertainties in the interpretation and application of existing, new, and proposed tax laws and regulations could materially affect tax obligations and effective tax rate.

Future Outlook

The company expects to continue incurring net losses for at least the next several years. It plans to invest in product development, market access, sales and marketing, clinical studies, and education initiatives. Interventional Dry Eye revenues are anticipated to ramp in 2026, and Interventional Glaucoma revenue is expected to grow. The company is expanding third-party manufacturing capacity outside of China starting in 2026 to diversify its manufacturing footprint and mitigate tariff impacts.

Management Comments

• Our mission is to develop transformative, interventional technologies that allow eyecare providers to procedurally elevate the standards of care – empowering people to keep seeing.
• Our objective is to develop and market products for use in new treatment paradigms and to create an interventional mindset in eyecare whereby our products may be used in procedures which supplant conventional outdated approaches.
• We believe the consistent therapeutic outcomes OMNI delivers are important for patients and surgeons alike, especially those considering a Standalone Procedure.
• Our goal is to establish OMNI and SION as standards of care for our customers and patients by continuing to grow their adoption and utilization in the existing Combination Cataract Market, which we believe remains underpenetrated.
• We believe TearCare has a compelling physiological profile to address gland obstructions caused by MGD.
• Our goals with the development of TearCare are to (i) fully transform the current outdated treatment paradigm based primarily on over-the-counter (OTC) and prescription eyedrops, both of which do not address obstruction of the meibomian glands, the primary root cause of MGD, and (ii) establish use of TearCare as the standard of care for the millions of patients suffering from evaporative DED caused by MGD.
• We aim and expect to be a clinical leader in every eyecare segment we enter, and we seek to achieve all criteria in our product development projects.
• We believe treatment decisions should be evidence-based and hold ourselves to the highest clinical and ethical standards.
• We believe this expertise is crucial to achieve our market development objectives in our Interventional Glaucoma and Interventional Dry Eye businesses.
• We believe the rates for facility and physician reimbursement in both settings reflect attractive and reasonable payments to cover all of our customers costs and economic needs related to glaucoma treatments using OMNI and SION.
• We believe the current Rx and OTC dry eye drop market is dominated by eyedrops that do not address the underlying causes of MGD and that TearCare has the potential to offer a better standard of care for evaporative dry eye patients and reduce overall costs for payor.
• We believe our focus on developing and marketing intuitively designed products that are intended to restore the eyes natural physiological function by addressing underlying causes of eye disease will be an important factor in our future success.
• We believe that the success of our business will depend, in part, on our ability to attract and retain qualified personnel.
• We believe that our continued success is reliant on the ability to attract, develop and retain top talent.
• We believe our product development approach is a key differentiator of our team and our company.
• We believe this level of operational and commercial progress relative to our total capital investment to date compares favorably to medical technology peers and we seek to design products that can achieve attractive long-term gross margins.

Industry Context

StockSavvy.ai notes that the ophthalmic medical device industry is highly competitive and subject to rapid change, with new product introductions and alternative therapies constantly emerging. The company operates in the Interventional Glaucoma and Interventional Dry Eye segments, both of which are described as underserved with large market opportunities. The shift in reimbursement policies for MIGS procedures, particularly the non-coverage of multiple MIGS procedures with shunts/stents, reflects a broader trend of payor scrutiny on healthcare costs and treatment efficacy. The company's focus on generating robust clinical and health economic data (BIA, CUA) for TearCare is a direct response to the industry's need for evidence-based reimbursement justification, especially as the dry eye market seeks to move beyond traditional eyedrops. The ongoing patent litigation with Alcon highlights the intense intellectual property battles common in high-value medical device markets.

Comparison to Industry Standards

• OMNI and SION compete with established players like Glaukos (iStent technologies, iDose TR), Alcon (Hydrus MicroStent), Iantrek (C-Rex, Alloflo), Nova Eye Medical (iTrack Advance), and New World Medical (Streamline, Via360).
• TearCare competes with DED product offerings such as Johnson & Johnson's Lipiflow Thermal Pulsation System and pharmaceutical companies like Abbvie and Novartis, which offer eyedrops.
• The company's overall gross margin of 86.2% and Interventional Glaucoma gross margin of 86.8% are generally strong for a medical device company, but are subject to competitive pricing and tariff impacts.
• The reduction in the Medicare Physician Fee Schedule for CPT code 66174 (canaloplasty) from approximately $950 in 2021 to $545 in 2026 indicates significant downward pressure on reimbursement for certain glaucoma procedures, potentially making them less attractive compared to alternatives or older, more established procedures.
• The SAHARA trial's finding of TearCare's superiority to Restasis eyedrops in tear breakup time (TBUT) improvement and non-inferiority in OSDI positions it favorably against a common pharmaceutical treatment for DED.
• The Budget Impact Analysis (BIA) and Cost Utility Analysis (CUA) for TearCare aim to demonstrate cost-effectiveness and health utility compared to prescription dry eye medications, a critical factor for gaining broader payor coverage in a cost-conscious healthcare environment.

Management Changes

Corporate Governance

Legal Proceedings

• Patent infringement lawsuit filed on September 16, 2021, in the U.S. District Court for the District of Delaware (C.A. No. 1:21-cv-01317) against Ivantis, Inc. (later amended to include Alcon Inc., Alcon Vision, LLC, and Alcon Research, LLC) alleging infringement of U.S. Patent Nos. 8,287,482, 9,370,443, 9,486,361, and 10,314,742 (and later 11,389,328).
• On April 26, 2024, the company was awarded a $34 million jury trial verdict against Alcon, comprising $5.5 million in lost profits damages and $28.5 million in royalty damages for commercial sales of the Hydrus Microstent.
• In March 2025, after failed mediation, the company and Alcon requested the Court to rule on post-trial motions and enter a judgment, which will be subject to appeal.
• In June 2025, Alcon filed petitions with the USPTO for ex parte reexaminations challenging the validity of the three patents asserted at trial, which the USPTO decided to proceed with in September 2025. The outcome of these reexamination proceedings could materially and adversely impact the jury verdict.
• The company is involved in trademark litigation in the United Kingdom and the European Union, initiated by another party, regarding the use of its OMNI trademark. An unfavorable outcome could require the company to abandon the OMNI trademark in these markets.

Stakeholder Impact

• Shareholders are impacted by declining revenue, ongoing losses, stock price volatility, potential dilution from future capital raises, and the uncertain outcome of significant patent litigation.
• Employees are affected by the Q3 2025 workforce reduction (20% global workforce) and the company's ability to attract and retain talent in a competitive market.
• Customers (ECPs, ASCs, HOPDs) are impacted by changes in reimbursement policies (e.g., non-coverage for multiple MIGS procedures, reduced CPT code 66174 payment), which can affect their willingness to adopt or continue using the company's products.
• Patients may benefit from the development of transformative interventional technologies for glaucoma and dry eye disease, but access may be limited by reimbursement challenges.
• Suppliers face risks due to the company's reliance on a limited number of third-party manufacturers, especially single-source providers in China, which creates supply chain risk.
• Creditors, specifically Hercules Capital, are secured by substantially all company assets, subject to financial covenants, and have an option to invest in future equity financing.

Next Steps

• Expand interventional dry eye commercialization infrastructure and customer engagements to increase TearCare utilization.
• Establish TearCare as the standard of care for reimbursed interventional dry eye procedural treatment among ECPs.
• Establish OMNI and SION as standards of care for interventional glaucoma treatment among MIGS-trained surgeons.
• Develop and expand the Standalone Market with OMNI, focusing on pseudophakic patients with uncontrolled IOP.
• Obtain and maintain appropriate reimbursement and coverage for Interventional Glaucoma technologies.
• Drive adoption and utilization of products by leveraging additional clinical trials and market education.
• Continue to create transformational and innovative interventional eyecare technology.
• Develop existing international markets.
• Continue to engage with other MACs, third-party payors, clinical societies, and stakeholders to support patient access for interventional meibomian gland disease procedures with the TearCare System.
• Take appropriate steps to prepare for the conversion of CPT code 0563T to a permanent Category I CPT code.
• Expand manufacturing to include additional facilities outside of China in 2026 to diversify manufacturing footprint and mitigate tariff impacts.
• Monitor developments and evaluate potential impacts of new U.S. tariffs and the U.S. Supreme Court ruling on IEEPA tariffs.
• The Court is expected to decide post-trial motions and enter a judgment in the Alcon patent litigation, which will be subject to appeal.
• The USPTO ex parte reexamination process for Alcon patents is currently underway.
• The company will continue to incur ongoing costs to comply with post-market clinical obligations in EU markets.
• The European Commission's proposed targeted simplification of medical device rules needs to be adopted by ordinary legislative procedure to become binding Union law.
• The company is currently evaluating the impact of adopting new accounting standards (ASU No. 2024-03, ASU 2025-06, ASU 2025-11).

Key Dates

Recommendation

The company faces significant headwinds, including declining revenue in both segments, substantial operating losses, and ongoing reimbursement challenges that directly impact product adoption. While cost-cutting measures and some positive clinical data for TearCare are noted, the overall financial performance and the uncertainty surrounding the Alcon patent litigation and its potential impact on damages and patent validity warrant a cautious 'hold' recommendation. Investors should monitor progress on reimbursement expansion for TearCare, the resolution of the Alcon litigation, and the effectiveness of cost-cutting initiatives.

Keywords

Ophthalmic Medical Devices, Glaucoma Treatment, Dry Eye Disease, MIGS, OMNI Surgical System, TearCare System, SION Surgical Instrument, SEC Filing, Annual Report, Financial Performance, Medical Technology, Reimbursement, Clinical Trials, Intellectual Property, Regulatory Compliance, Healthcare Industry, Corporate Governance, Risk Factors, Financial Results, Ophthalmology, Optometry, Glaukos, Alcon, Novartis, Johnson & Johnson, AbbVie, Iantrek, Nova Eye Medical, New World Medical